Back

Hemoglobin, anemia, and clinical outcomes in vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA)

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Congress committee e-posters choice in heart failure Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Justin Ezekowitz

University of Alberta, Edmonton (Canada)

46 More presentations in this session

Presentation thumbnail
Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes
Doctor A. Sharma (Montreal, CA)
Abstract Slides
Presentation thumbnail
SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis
Doctor V. Razuk (New York City, US)
Abstract Slides
Presentation thumbnail
Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis
Doctor G. Steiner-Gager (Vienna, AT)
Abstract Slides
Presentation thumbnail
Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin
Doctor J. Kolwelter (Erlangen, DE)
Abstract Slides
Presentation thumbnail
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Doctor M. Senni (Bergamo, IT)
Abstract Slides

Access the full session

Session thumbnail
Congress committee e-posters choice in heart failure

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Short-term changes in hemoglobin and changes in functional status, quality of life, and natriuretic peptides after initiation of dapagliflozin in heart failure with reduced ejection fraction
20 May 2023
thumbnail
Congress Presentation
Impact of moderate to severe anemia on clinical outcomes in patients with atrial fibrillation and coronary artery disease requiring percutaneous coronary intervention
2 September 2024
thumbnail
Congress Presentation
Blood pressure response and safety outcomes with vericiguat in the VICTORIA trial
30 June 2021
thumbnail
Congress Presentation
Prevalence of sideropenia and sideropenic anemia in patients hospitalized for heart failure
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources